XML 56 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue (Tables)
 3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Recognized Revenues From Strategic Partnerships and Other License Agreements
The Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
 Three Months Ended March 31,
 20222021
Seagen$312 $366 
AstraZeneca4,753 14,500 
Servier4,734 767 
Genentech1,189 — 
Total Revenue$10,988 $15,633 
Schedule of Potential Milestone Payments
Under the Company’s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions):
 Research, Development, Regulatory & Commercial MilestonesSales Milestones
AstraZeneca$900 $4,100 
Servier133 100 
Seagen754 450 
Boston Pharmaceuticals88 265 
Genentech844 600 
Total potential milestone payments$2,719 $5,515